Zachariah McIver

Zachariah McIver has a diverse work experience in the field of Hematology and Oncology. Zachariah is currently working as the Vice President at Janux Therapeutics since June 2023. Prior to this, they served as the Executive Medical Director, Product Team Lead, Early Drug Development, Oncology at Amgen from November 2021 to May 2023.

At Amgen, Zachariah was responsible for leading cross-functional global product teams and clinical development programs for various oncology indications. Zachariah contributed to the development of MCL-1 inhibitor small molecule, anti-BCMA BITE, and anti-PSMA BiTE programs.

Before joining Amgen, Zachariah held positions at Wake Forest School of Medicine and Wake Forest University School of Medicine as an Associate Professor and Assistant Professor, respectively. In these roles, they performed clinical duties in the department of Hematology/Oncology, including attending on the bone marrow transplant ward and outpatient clinics, as well as supervising and teaching fellows and medical students.

Additionally, Zachariah served as the Medical Director of Cell Therapy Laboratory at Wake Forest University School of Medicine, where they coordinated cell therapy preparation and administration.

Prior to their time at Wake Forest, Zachariah worked as an Assistant Professor at Tulane University and as a Hematology and Oncology specialist at the National Heart, Lung, and Blood Institute, NIH.

Zachariah began their medical career at the Cleveland Clinic as an Internal Medicine specialist.

Overall, Zachariah McIver has extensive experience in clinical practice, leadership roles, and clinical development in the field of Hematology and Oncology.

Zachariah McIver's education history starts with their Bachelor of Science degree in Physics from the University of Oregon, which they completed in 1994. Zachariah then pursued their Doctor of Medicine (DO) degree at Ohio University, finishing their studies in 2004. Following that, Zachariah continued their education at Wake Forest University, where they obtained a Doctor of Philosophy (PhD) degree in Molecular Medicine and Translational Sciences in 2017.